Genetics News and Research

Latest Genetics News and Research

HSR Act applicable to LabCorp’s acquisition of Genzyme

Laboratory Corporation of America Holdings today announced that it has received early termination from the Federal Trade Commission of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, applicable to the acquisition of Genzyme Genetics, a business unit of Genzyme Corp. by LabCorp.

19 Nov 2010

Sekisui enters asset purchase agreement to acquire Genzyme's Diagnostic products

Genzyme Corporation today announced that it has entered into an asset purchase agreement under which Sekisui Chemical Co., Ltd. will acquire Genzyme's Diagnostic products business for $265 million in cash.

19 Nov 2010

OSEO awards €10.4 million to DIPPAL project targeting Alzheimer's disease

The biotech companies PHARNEXT and BIOSYSTEMS INTERNATIONAL, the Bordeaux Hospital where CMRR is located, the university Bordeaux Segalen and Inserm (the center U897 "Epidemiology and Biostatistics") have joined forces to carry out the DIPPAL2i project. This innovative research and industrial development project is targeting Alzheimer's disease (AD) and has attracted significant financial support from OSEO (the French state innovation agency).

18 Nov 2010

New findings reveal complexities in close chemical combat waged among bacteria

Like all organisms, bacteria must compete for resources to survive, even if it means a fight to the death. New research led by scientists from the University of North Carolina at Chapel Hill School of Medicine and the University of California, Santa Barbara, describes new complexities in the close chemical combat waged among bacteria.

18 Nov 2010

Researchers find clue behind dementia development

Researchers at the Mayo Clinic campus in Florida have found a clue as to how some people develop a form of dementia that affects the brain areas associated with personality, behavior, and language.

18 Nov 2010

Myrexis presents data on MPC-9528 cancer metabolism inhibitor at EORTC/NCI/AACR Symposium

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today presented two posters at the 22nd European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium on "Molecular Targets and Cancer Therapeutics," in Berlin, Germany.

18 Nov 2010

New method to improve coordinating care in children with chronic conditions

Children with chronic health conditions such as cystic fibrosis, type 1 diabetes, sickle cell diseases and cerebral palsy represent less than two percent of the population but can consume more than 50 percent of resources at children's hospitals throughout the country. Coordinating care for these children has historically been difficult because hospitals have varying methods to identify them in their systems.

17 Nov 2010

Isis, Xenon enter collaboration to discover and develop antisense drugs for AI

Isis Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc. announced today a new collaboration to discover and develop antisense drugs as novel treatments for the common disease anemia of inflammation (AI).

16 Nov 2010

MLL purchases Access Array, EP1 Systems for high-throughput deep-resequencing analysis

Fluidigm Corporation announced today that MLL Munich Leukemia Laboratory has purchased Access Array and EP1 Systems. The Access Array System is being used in combination with Roche's 454 GS FLX and GS Junior sequencing instruments, enabling high-throughput targeted deep-resequencing analyses.

16 Nov 2010

Study confirms healthy lifestyle has the biggest impact on cardiovascular health

Two large studies from Northwestern Medicine confirm a healthy lifestyle has the biggest impact on cardiovascular health. One study shows the majority of people who adopted healthy lifestyle behaviors in young adulthood maintained a low cardiovascular risk profile in middle age.

16 Nov 2010

4SC to present development of resminostat and preclinical drug candidates at EORTC-NCI-AACR symposium

4SC, a drug discovery and development company focused on autoimmune and cancer indications, today announced that it will present four posters and respective abstracts that highlight the development of its lead oncology compound resminostat and several preclinical drug candidates at the 22nd EORTC-NCI-AACR symposium from 16 - 19 November, 2010 in Berlin, Germany.

16 Nov 2010

Researchers develop new vaccine delivery system for rotavirus infection

Researchers have developed a promising new approach to vaccination for rotavirus, a common cause of severe diarrheal disease that is responsible for approximately 500,000 deaths among children in the developing world every year.

16 Nov 2010

OtoSCOPE method offers single-run genetic testing for hearing loss

Pinpointing the exact genetic cause of inherited deafness has always involved sequencing one gene at a time, a process that can take up to a year and cost roughly $1,000 per gene. It would cost around $75,000 to test all known deafness causing genes using this approach. Now University of Iowa researchers working with colleagues at Baylor College of Medicine have developed a test that can screen all of the genes known to cause deafness in a single run, in one to three months and for about $2,000.

16 Nov 2010

Fisetin slows onset of motor problems, delays death in three models of Huntington's disease: Study

Fisetin, a naturally occurring compound found in strawberries and other fruits and vegetables, slows the onset of motor problems and delays death in three models of Huntington's disease, according to researchers at the Salk Institute for Biological Studies. The study, published in the online edition of Human Molecular Genetics, sets the stage for further investigations into fisetin's neuroprotective properties in Huntington's and other neurodegenerative conditions.

16 Nov 2010

Celladon presents data on Phase 2 CUPID clinical trial for advanced heart failure at American Heart Association

Targeted Genetics Corporation announced that its partner, Celladon Corporation, today presented 12-month data from its Phase 2 CUPID clinical trial of MYDICAR demonstrating significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.

16 Nov 2010

Scientists discover new genetic variants linked to bowel cancer

Cancer Research UK-funded scientists have discovered four new genetic variants linked to bowel cancer by combining data from three major genome studies, reveals a study published in Nature Genetics.

16 Nov 2010

National health disparities conference wraps up with creative approaches, expectations for new healthcare reform

Focusing on the disparities in the quality of health care across demographic groups, the Fourth Annual National Conference on Health Disparities brought together White House officials and national and local healthcare executives to address a series of key questions about non-medical determinants of health quality and to recommend strategies to bring more equitable healthcare access to the underserved. The determinants discussed at the four-day-long conference, which began November 10, 2010 and concluded Saturday, November 13, 2010, included education levels, health literacy, poverty, public safety, community design, access to care, environmental quality and personal, government and corporate responsibility.

15 Nov 2010

PGxHealth presents results from studies using FAMILION genetic testing at 2010 AHA

Clinical Data, Inc., today announced that results of studies using its FAMILION® genetic testing were presented at the 2010 American Heart Association (AHA) meeting. PGxHealth, a division of Clinical Data, together with its collaborators, presented results from the largest, most comprehensive studies of genetic variation associated with certain cardiac conditions that were revealed using FAMILION testing.

15 Nov 2010

Adeona third quarter total net revenues increase to $289,898

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced its third quarter 2010 financial results as well as recent clinical and operational achievements.

15 Nov 2010

Spontaneous mutations can cause mental retardation

Dutch geneticists affiliated with the Radboud University Nijmegen Medical Centre present as a novel research paradigm that spontaneous mutations are an important cause of mental retardation.

15 Nov 2010

Genetics News and Research

Latest Genetics News and Research

HSR Act applicable to LabCorp’s acquisition of Genzyme

Sekisui enters asset purchase agreement to acquire Genzyme's Diagnostic products

OSEO awards €10.4 million to DIPPAL project targeting Alzheimer's disease

New findings reveal complexities in close chemical combat waged among bacteria

Researchers find clue behind dementia development

Myrexis presents data on MPC-9528 cancer metabolism inhibitor at EORTC/NCI/AACR Symposium

New method to improve coordinating care in children with chronic conditions

Isis, Xenon enter collaboration to discover and develop antisense drugs for AI

MLL purchases Access Array, EP1 Systems for high-throughput deep-resequencing analysis

Study confirms healthy lifestyle has the biggest impact on cardiovascular health

4SC to present development of resminostat and preclinical drug candidates at EORTC-NCI-AACR symposium

Researchers develop new vaccine delivery system for rotavirus infection

OtoSCOPE method offers single-run genetic testing for hearing loss

Fisetin slows onset of motor problems, delays death in three models of Huntington's disease: Study

Celladon presents data on Phase 2 CUPID clinical trial for advanced heart failure at American Heart Association

Scientists discover new genetic variants linked to bowel cancer

National health disparities conference wraps up with creative approaches, expectations for new healthcare reform

PGxHealth presents results from studies using FAMILION genetic testing at 2010 AHA

Adeona third quarter total net revenues increase to $289,898

Spontaneous mutations can cause mental retardation

eBook: Using iPSCs models for human disease research and drug discovery eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging